Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma

• Main Authors: Shuto Negishi (Author), James H. Girsch (Author), Elizabeth L. Siegler (Author), Evandro D. Bezerra (Author), Kotaro Miyao (Author), R. Leo Sakemura (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Clinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown high overall response rates in patients with relapsed/refractory B-cell malignancies. CART19 cell therapy has been approved by the US Food and Drug Administration for patients who relapsed less than 12 months a...